Lead Product(s): Undisclosed
Therapeutic Area: Oncology
Highest Development Status: Undisclosed Product Type: Small molecule
Deal Size: $2,550.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration January 06, 2020
Under the terms of the agreement, Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.